Successful treatment with a short course of remdesivir in a case of prolonged COVID-19 in a lymphoma patient

Mikael Kajovaa Department of Infectious Diseases, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, FinlandCorrespondence[email protected]

Eliisa Kekäläinenb HUS Diagnostic Center, HUSLAB, Clinical Microbiology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland;c Translational Immunology Research Program and Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland

Veli-Jukka Anttilaa Department of Infectious Diseases, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

Juuso Paajanend Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

Pages 455-459 | Received 03 Nov 2021, Accepted 07 Jan 2022, Published online: 27 Jan 2022

Cite this article
https://doi.org/10.1080/23744235.2022.2028896
CrossMark

Full Article
Figures & data
References
Supplemental
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

References

Wang Q, Berger NA, Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol. 2021;7(2):220–227.
PubMed Web of Science ®Google Scholar
Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–436.
PubMed Web of Science ®Google Scholar
Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383(26):2586–2588.
PubMed Web of Science ®Google Scholar
Haveri A, Smura T, Kuivanen S, et al. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. Euro Surveill. 2020;25(11):2000266.
Google Scholar
Jääskeläinen AJ, Kuivanen S, Kekäläinen E, et al. Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation. J Clin Virol. 2020;129:104512.
PubMed Web of Science ®Google Scholar
Ahava M, Kurkela S, Kuivanen S, et al. Detection of SARS-CoV-2 nucleocapsid antigen from serum can aid in timing of COVID-19 infection. Preprint, MedRxiv. 2021.
Google Scholar
Baang JH, Smith C, Mirabelli C, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021;223(1):23–27.
PubMed Web of Science ®Google Scholar
Camprubí D, Gaya A, Marcos MA, et al. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir. Int J Infect Dis. 2021;104:379–381.
PubMed Web of Science ®Google Scholar
Malsy J, Veletzky L, Heide J, et al. Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19. Clin Infect Dis. 2020;73:e4020–e4024.
Web of Science ®Google Scholar
Ormazabal Vélez I, Induráin Bermejo J, Espinoza Pérez J, et al. Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma. Transfus Apher Sci. 2021;60(3):103104.
PubMed Web of Science ®Google Scholar
Fujii H, Tsuji T, Sugitani M, et al. Prolonged persistence of SARS-CoV-2 infection during a + AVD therapy for classical hodgkin’s lymphoma: a case report. Curr Probl Cancer. 2021;45(6):100739.
PubMed Web of Science ®Google Scholar
Rnjak D, Ravlić S, Šola AM, et al. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients? Transfus Clin Biol. 2021;28:264–270.
PubMed Web of Science ®Google Scholar
Simioli F, Martino M, Annunziata A, et al. Therapeutic approach for severe COVID-19 and immunocompromised patients. A case series. Respir Med Case Rep. 2021;33:101397.
PubMed Web of Science ®Google Scholar
Kenig A, Ishay Y, Kharouf F, et al. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products. Clin Immunol. 2021;227:108723.
PubMed Web of Science ®Google Scholar
Pelcovits A, Pandita A, Farmakiotis D, et al. Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR. Leuk Res. 2021;100:106473.
PubMed Web of Science ®Google Scholar
Reuken PA, Stallmach A, Pletz MW, et al. Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection. Leukemia. 2021;35(3):920–923.
PubMed Web of Science ®Google Scholar
Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861–880.
PubMed Web of Science ®Google Scholar
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
PubMed Web of Science ®Google Scholar
Hoffmann MS, Ganguly S. Delayed COVID-19 respiratory failure in patients with lymphoma on rituximab-based chemoimmunotherapy. Clin Lymphoma Myeloma Leuk. 2021;21:e548–e550.
PubMed Web of Science ®Google Scholar
Betrains A, Godinas L, Woei AJF, et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol. 2021;192(6):1100–1105.
PubMed Web of Science ®Google Scholar
Duléry R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96(8):934–944.
PubMed Web of Science ®Google Scholar
Aleissa MM, Silverman EA, Paredes Acosta LM, et al. New perspectives on antimicrobial agents: remdesivir treatment for COVID-19. Antimicrob Agents Chemother. 2020;65(1):e01814–20.
PubMed Web of Science ®Google Scholar
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 - Final report. N Engl J Med. 2020;383(19):1813–1826.
PubMed Web of Science ®Google Scholar
Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for covid-19 - Interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497–511.
PubMed Web of Science ®Google Scholar
Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe covid-19 in outpatients. N Engl J Med. 2021. DOI:https://doi.org/10.1056/NEJMoa2116846
Google Scholar
Monin L, Laing AG, Muñoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22:765–778.
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Successful treatment with a short course of remdesivir in a case of prolonged COVID-19 in a lymphoma patient

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Successful treatment with a short course of remdesivir in a case of prolonged COVID-19 in a lymphoma patient

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date